Resveratrol's Effects on Inflammation and Oxidative Stress in Chronic Kidney Disease

Universidade Federal Fluminense

Status and phase: Completed; Phase 3

Conditions: Chronic Renal Insufficiency

Treatments: Dietary Supplement: Placebo; Dietary Supplement: Resveratrol

Study type: Interventional

Funder types: Other

Identifiers

NCT02433925

DeniseMafra

Details and patient eligibility

About

Inflammation and oxidative stress are common findings in patients with Chronic Kidney Disease (CKD) undergoing conservative treatment, in addition to being associated with atherosclerotic process, are related also to the progression of CKD. In this regard, resveratrol, a phenolic compound with recognized antioxidant and anti-inflammatory properties, can play an important role in the control of metabolic disorders associated with CKD, since it can modulate the mechanisms involved in inflammation and oxidative stress cycle. Resveratrol is capable of promoting the activation of the transcription-related factor-2 nuclear factor erythroid factor 2 (Nrf2) , a nuclear factor with anti-inflammatory properties, and SIRT-1, a protein also associated with the reduction of inflammation. These two factors, in their turn, are able to inhibit / antagonize the activity of the nuclear factor κB (NF-kB), a transcription factor that participates in the inflammatory response. Although it is a promising treatment, there are no studies evaluating the effects of resveratrol supplementation in patients with CKD. Thus, this study aims to evaluate the effects of resveratrol supplementation on inflammation and oxidative stress in patients undergoing conservative treatment of CKD.

Enrollment: 20 patients

Sex: All

Ages: 45 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Chronic kidney disease patients in stages 3 or 4, undergoing conservative treatment

Exclusion criteria

• Patients with diabetes mellitus, AIDS, inflammatory or infectious diseases, pregnant women, smokers and those using antioxidant supplements

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

20 participants in 2 patient groups, including a placebo group

Supplement B

Active Comparator group

Description:

Administration of 500mg of trans-resveratrol per day, for 4 weeks

Treatment:

Dietary Supplement: Resveratrol

Supplement A

Placebo Comparator group

Description:

Administration of 500mg of placebo per day, for 4 weeks

Treatment:

Dietary Supplement: Placebo